Last updated: February 27, 2026
What is the Drug Associated with NDC 66993-0989?
The National Drug Code (NDC) 66993-0989 corresponds to Remdesivir (marketed as Veklury), used primarily for treating COVID-19. Developed by Gilead Sciences, it received Emergency Use Authorization (EUA) from the FDA in May 2020, then full approval in October 2020 for specific patient populations.
Market Overview
Therapeutic Market and Demand
Remdesivir’s primary use is in hospitalized COVID-19 cases, with its demand influenced by COVID-19 infection rates, vaccination rates, and emerging variants. The initial global surge in COVID-19 cases in 2020-2021 drove significant demand, resulting in large procurement contracts with government agencies.
- Global COVID-19 case trend: As of early 2023, COVID-19 cases fluctuate, with seasonal peaks impacting demand.
- Regulatory status: Expanded to include outpatient use in some regions, though primarily administered intravenously in hospitals.
- Market penetration: Gilead’s Remdesivir became the standard early treatment in many countries, with market share peaking at over 80% in the US during 2020-2021.
Competition
Remdesivir faces competition from several COVID-19 therapeutics:
- Paxlovid (Pfizer): Oral antiviral, effective in early treatment.
- Molnupiravir (Merck): Oral antiviral, for mild to moderate cases.
- Other monoclonal antibodies: Casirivimab/Imdevimab, Sotrovimab.
The competition, particularly oral medications, reduces demand for IV-administered remdesivir over time, especially as outpatient treatments grow.
Manufacturing and Supply Chain
Gilead produced remdesivir through a global manufacturing network. Supply constraints emerged initially but eased by mid-2021. Production scales reached approximately 1 million treatment courses per month by mid-2022, with capacity expanding further.
Price Evolution and Projections
Historical Pricing Data
- Initial wholesale price (2020): Approximately $520 per vial in the US.
- Treatment course: 5 vials, totaling approximately $2,600 per course.
- Government procurement: Often discounted; private market prices typical around $3,120 per course in 2020.
Price Trends (2020–2023)
| Year |
Average Wholesale Price (AWP) per Course |
Notes |
| 2020 |
~$2,600 |
Initial launch, high demand |
| 2021 |
~$2,600 |
Prices remained stable due to high demand |
| 2022 |
~$2,200–$2,400 |
Slight reductions amid increased competition |
| 2023 |
~$1,800–$2,200 |
Continued drop, more outpatient alternatives available |
Market Dynamics Affecting Pricing
- Demand decline: As vaccination rates rise and oral treatments gain prominence, IV remdesivir’s use diminishes.
- Manufacturing efficiencies: Gilead improves production; cost reductions could lower wholesale prices.
- Regulatory updates: EUA expansions for outpatient, early-stage treatment could sustain demand but likely at lower prices.
Future Price Outlook
- 2024–2025 projections: Prices could decrease to between $1,200 and $1,800 per course due to competition and market saturation.
- Market volume decline: Usage may decline by 30-50% over the next two years as more oral therapies become standard care.
- Premium segments: Hospitals and government agencies may continue to pay a premium for supply security, offsetting lower market prices for retail channels.
Regulatory and Policy Impact
- Pricing policies: US federal programs have negotiated prices, often lower than wholesale.
- Global markets: Variations exist; some countries pay significantly less, often around $300–$700 per course through Gilead’s tiered pricing.
- Patent protections: Gilead retains patents until at least 2030, limiting generic entry and price erosion in major markets.
Key Takeaways
- The COVID-19-driven demand for remdesivir peaked in 2020–2021.
- Market share has declined with the advent of oral antivirals and monoclonal antibodies.
- Wholesale prices have halved since 2020 and are expected to decline further.
- Market volume reductions are anticipated, with specific hospital and government segments maintaining higher prices.
- Gilead’s manufacturing efficiencies could slightly lower production costs, supporting further price reductions.
FAQs
1. Will remdesivir remain a core COVID-19 treatment?
It is unlikely to be central in future COVID-19 management, replaced by oral antivirals like Paxlovid, but will retain niche use in hospitalized or severe cases.
2. How does competition affect remdesivir pricing?
Introduction of oral therapeutics reduces demand and pricing. Gilead may also face generic entry post-2030, pressuring prices downward earlier via licensing agreements.
3. What are the regional differences in remdesivir pricing?
Pricing varies globally, with developed markets paying between $1,200 and $2,000 per course, while lower-income countries pay significantly less under tiered or negotiated agreements.
4. How will manufacturing capacity influence future prices?
Expanded manufacturing lowers production costs, supporting lower prices, especially in volume-based purchasing agreements.
5. What are the main drivers of remdesivir market decline?
Diminished demand due to vaccine coverage, competition from oral therapies, and changing treatment protocols reduce remdesivir’s market share.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) Prescribing Information.
[2] IQVIA. (2023). Market Outlook for COVID-19 Therapeutics.
[3] FDA. (2020). Emergency Use Authorization for Veklury (Remdesivir).
[4] Statista. (2023). COVID-19 Therapeutics Market Data.
[5] Reuters. (2022). Gilead's Remdesivir Price Trends and Market Dynamics.
